Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays.

导出 LinkOut

翻译打印收藏纠错

作者： Christos,Fotis ^[1] ; Nikolaos,Meimetis ^[1] ; Nikos,Tsolakos ^[2] ; Marianna,Politou ^[3] ; Karolina,Akinosoglou ^[4] ; Vaia,Pliaka ^[2] ; Angeliki,Minia ^[2] ; Evangelos,Terpos ^[3] ; Ioannis P,Trougakos ^[5] ; Andreas,Mentis ^[6] ; Markos,Marangos ^[4] ; George,Panayiotakopoulos ^[7] ; Meletios A,Dimopoulos ^[3] ; Charalampos,Gogos ^[4] ; Alexandros,Spyridonidis ^[8] ; Leonidas G,Alexopoulos ^[9]

作者单位： Biomedical Systems Laboratory, National Technical University of Athens, Athens, Greece. ^[1] ProtATonce Ltd, Demokritos Science Park, Athens, Greece. ^[2] Department of Clinical Therapeutics, Alexandra General Hospital, National and Kapodistrian University of Athens, Athens, Greece. ^[3] Division of Infectious Diseases, Department of Internal Medicine, University Hospital of Patras, Patras, Greece. ^[4] Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece. ^[5] Medicinal Microbiology Laboratory, Hellenic Pasteur Institute, Athens, Greece. ^[6] Pharmacology Laboratory, University of Patras, Patras, Greece.;National Public Health Organization, Athens, Greece. ^[7] Department of Internal Medicine, BMT Unit and CBMDP Donor Center, University of Patras, Patras, Greece. spyridonidis@upatras.gr. ^[8] Biomedical Systems Laboratory, National Technical University of Athens, Athens, Greece. leo@mail.ntua.gr.;ProtATonce Ltd, Demokritos Science Park, Athens, Greece. leo@mail.ntua.gr. ^[9]